AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Mepgud GV 1mg/500mg/0.2mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Rowlinges Life Science

Salt Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Mepgud GV 1mg/500mg/0.2mg Tablet ER

Glycemia-X Trio (1mg/500mg/0.2mg) extended-release tablets are classified as antidiabetic medications. This triple-combination therapy is indicated for managing type 2 diabetes in adults, effectively regulating blood glucose. Glycemia-X Trio should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication is a component of a comprehensive diabetes management plan, encompassing a healthy diet, regular physical activity, and weight management as directed by your doctor. The most prevalent adverse effect is hypoglycemia (low blood sugar). Learn to recognize its symptoms—sweating, dizziness, headache, tremors—and know how to manage them. Regular meals and carrying a rapid-acting glucose source (e.g., sugary snacks or juice) are essential preventative measures. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated for individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before initiating treatment. Consult your doctor before using Glycemia-X Trio if pregnant or breastfeeding. Regular blood glucose monitoring is necessary; your doctor may also order blood tests to assess blood cell counts and liver function.

Primary Ingredients of Mepgud GV 1mg/500mg/0.2mg Tablet ER

There is no text provided to rephrase.

Uses of Mepgud GV 1mg/500mg/0.2mg Tablet ER

Managing Type 2 Diabetes

Major Benefits of Mepgud GV 1mg/500mg/0.2mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Mepgud GV 1mg/500mg/0.2mg Extended-Release tablet whole; do not break, crush, or chew it. Administer this medication on an empty stomach.

Common Side effects of Mepgud GV 1mg/500mg/0.2mg Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Mepgud GV 1mg/500mg/0.2mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Mepgud GV 1mg/500mg/0.2mg Extended-Release tablet whole; do not break, chew, or crush it. Administer on an empty stomach.

How Mepgud GV 1mg/500mg/0.2mg Tablet ER works:

Extended-release tablet Mepgud GV contains a triple combination of 1mg, 500mg, and 0.2mg of three distinct antidiabetic agents.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Mepgud GV 1mg/500mg/0.2mg Tablet ER with alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Mepgud GV tablet (1mg/500mg/0.2mg) might pose risks during pregnancy. While human research is scarce, animal studies indicate potential harm to a fetus. A physician will assess the potential advantages against any risks before prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Mepgud GV tablets (1mg/500mg/0.2mg) are likely unsafe for breastfeeding mothers. Available data from humans indicate potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

The extended-release Mepgud GV 1mg/500mg/0.2mg tablet is likely unsafe for individuals with kidney impairment and its use should be strictly avoided. A physician's consultation is advised. Furthermore, this medication is contraindicated in patients exhibiting severe kidney dysfunction.

LiverLiverCAUTION

Patients with liver impairment should use Mepgud GV 1mg/500mg/0.2mg Tablet ER cautiously, potentially requiring dosage modification. A physician's consultation is advised. Individuals with mild to moderate hepatic dysfunction typically begin on a reduced Mepgud GV 1mg/500mg/0.2mg Tablet ER dose; however, its administration is contraindicated in those with severe liver disease.

What if you forget to take Mepgud GV 1mg/500mg/0.2mg Tablet ER :

Should you forget to take a Mepgud GV 1mg/500mg/0.2mg Tablet ER, administer it immediately upon recollection. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Mepgud GV 1mg/500mg/0.2mg Tablet ER

LabelValue
Developing Habits No.
Type of Therapy Diabetes Management

FAQs on Mepgud GV 1mg/500mg/0.2mg Tablet ER

Mepgud GV 1mg/500mg/0.2mg Extended-Release Tablets combine glimepiride, metformin, and voglibose to manage type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas; metformin reduces liver glucose production and enhances insulin sensitivity; and voglibose, an alpha-glucosidase inhibitor, lowers post-meal blood sugar. This medication is not suitable for type 1 diabetes.
Mepgud GV 1mg/500mg/0.2mg Tablet ER may cause common side effects including hypoglycemia, nausea, diarrhea, altered taste perception, flatulence, abdominal pain, headache, rash, and respiratory infection.
Mepgud GV 1mg/500mg/0.2mg Tablet ER is contraindicated in patients allergic to its components or excipients, those with moderate to severe kidney disease, and those with inflammatory bowel disease, colonic ulcers, or underlying metabolic acidosis (including diabetic ketoacidosis).
Combining Mepgud GV 1mg/500mg/0.2mg Tablet ER with alcohol is unsafe. This combination can worsen low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Mepgud GV 1mg/500mg/0.2mg Tablet ER can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry glucose tablets, honey, or fruit juice for emergencies.
Store this medication in its original, tightly closed container, following the storage instructions provided. Discard any unused medication and ensure it remains inaccessible to children, pets, and others.
Mepgud GV 1mg/500mg/0.2mg...
82
MRP 100
18% off